Evidence map›Paper›PMID 39076084›Full record

ArticleAmerican journal of physiology. Lung cellular and molecular physiology2024

Longitudinal importance of the soluble receptor for advanced glycation end-products in nonintubated hospitalized patients with COVID-19 pneumonia.

Katherine D Wick, Lianne Siegel, Cathryn Oldmixon, Jens D Lundgren, B Taylor Thompson, Chayse Jones, Carolyn Leroux, Michael A Matthay, ACTIV-3/TICO Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Lung cellular and molecular physiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katherine D WickCardiovascular Research Institute, University of California, San Francisco, California, United States.ORCID 0000-0001-9070-5490
Lianne SiegelDivision of Biostatistics and Health Data Science, University of Minnesota, Minneapolis, Minnesota, United States.
Cathryn OldmixonBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, United States.
Jens D LundgrenCHIP (Centre of Excellence for Health, Immunity and Infections), Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
B Taylor ThompsonDivision of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States.
Chayse JonesCardiovascular Research Institute, University of California, San Francisco, California, United States.
Carolyn LerouxCardiovascular Research Institute, University of California, San Francisco, California, United States.
Michael A MatthayCardiovascular Research Institute, University of California, San Francisco, California, United States.ORCID 0000-0003-3039-8155
ACTIV-3/TICO Study Group

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating CenterOT2HL156812 · NHLBI · RESEARCH TRIANGLE INSTITUTE · PI NOLEN, TRACY L, THOMAS, SONIA M · 2020 to 2024
$1270.7M
Precision Medicine in the Acute Respiratory Distress SyndromeR35HL140026 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CALFEE, CAROLYN · 2018 to 2024
$6.8M
Modeling chikungunya virus infection in a vascularized bone modelR21AI140026 · NIAID · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DUAN, BIN, REID, PATRICK M · 2018 to 2019
$419k
HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) R35HL140026HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R35HL140026Leidos (Leidos Holdings, Inc.)NCI NIH HHS 75N91019D00024NHLBI NIH HHS OT2 HL156812NHLBI NIH HHS R35 HL140026
6 · The paper itself

Abstract

The soluble receptor for advanced glycation end-products (sRAGE) is a marker of alveolar type I cell injury associated with outcomes in COVID-19 pneumonia. How plasma sRAGE changes over time and whether it remains associated with long-term clinical outcomes beyond a single measurement in COVID-19 have not been well studied. We studied two cohorts in randomized clinical trials of monoclonal antibody treatment for COVID-19 (bamlanivimab and tixagevimab/cilgavimab). We first studied the association between baseline plasma sRAGE and 90-day clinical outcomes, which had been previously demonstrated in the bamlanivimab cohort, among hospitalized patients with COVID-19 supported with high-flow nasal oxygen (HFNO) or noninvasive ventilation (NIV) in the tixagevimab/cilgavimab study. Next, we investigated the relationship between

Indexed as

COVID-19HospitalizationReceptor for Advanced Glycation End ProductsSARS-CoV-2AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingBiomarkersCOVID-19 Drug TreatmentFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntibodies, NeutralizingbamlanivimabBiomarkersReceptor for Advanced Glycation End Productsalveolar epitheliumbiomarkerCOVID-19pneumoniaRAGE

Identifiers

PMID39076084
PMCPMC11563646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.